Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Tiprelestat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- 17 Jul 2018 According to Proteo Biotech media release, trial commence with recruitment in 2018.
- 30 Apr 2018 Status changed from planning to not yet recruiting.
- 23 Jan 2018 New trial record